Published in J Neurosci on April 15, 2003
Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron (2010) 4.76
Toxin-induced models of Parkinson's disease. NeuroRx (2005) 2.67
A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol (2008) 2.44
Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci (2008) 2.20
Lewy bodies. Proc Natl Acad Sci U S A (2006) 2.15
Increased heat shock protein 70 gene expression in the brains of cocaine-related fatalities may be reflective of postdrug survival and intervention rather than excited delirium. J Forensic Sci (2012) 2.06
Lysosomal degradation of alpha-synuclein in vivo. J Biol Chem (2010) 1.82
The function of α-synuclein. Neuron (2013) 1.63
Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol Brain (2008) 1.61
Mitochondrial complex I inhibition is not required for dopaminergic neuron death induced by rotenone, MPP+, or paraquat. Proc Natl Acad Sci U S A (2008) 1.61
Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model. Am J Pathol (2007) 1.52
Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease. Clin Neurosci Res (2006) 1.50
Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol (2008) 1.45
Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression. Synapse (2007) 1.41
Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease. Environ Health Perspect (2011) 1.30
Potential developmental neurotoxicity of pesticides used in Europe. Environ Health (2008) 1.25
α-Synuclein negatively regulates protein kinase Cδ expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity. J Neurosci (2011) 1.16
Gene-environment interactions: key to unraveling the mystery of Parkinson's disease. Prog Neurobiol (2011) 1.14
A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice. Neurotherapeutics (2012) 1.11
Gene-environment interactions in Parkinson's disease: the importance of animal modeling. Clin Pharmacol Ther (2010) 1.07
The transgenic overexpression of alpha-synuclein and not its related pathology associates with complex I inhibition. J Biol Chem (2010) 1.05
JNK3 mediates paraquat- and rotenone-induced dopaminergic neuron death. J Neuropathol Exp Neurol (2010) 1.04
Prolonged toxicokinetics and toxicodynamics of paraquat in mouse brain. Environ Health Perspect (2007) 1.04
Mitochondrial Dysfunction: The Road to Alpha-Synuclein Oligomerization in PD. Parkinsons Dis (2011) 0.99
Protein aggregation in retinal cells and approaches to cell protection. Cell Mol Neurobiol (2005) 0.96
Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson's disease. Mol Neurodegener (2009) 0.95
Upregulation of α-synuclein during localized radiation therapy signals the association of cancer-related fatigue with the activation of inflammatory and neuroprotective pathways. Brain Behav Immun (2012) 0.94
Vulnerability of mesostriatal dopaminergic neurons in Parkinson's disease. Front Neuroanat (2010) 0.92
Modulation of alpha-synuclein expression in transgenic animals for modelling synucleinopathies--is the juice worth the squeeze? Neurotox Res (2008) 0.91
Multifactorial theory applied to the neurotoxicity of paraquat and paraquat-induced mechanisms of developing Parkinson's disease. Lab Invest (2016) 0.91
The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease. Antioxid Redox Signal (2009) 0.90
α-Synuclein levels modulate Huntington's disease in mice. Hum Mol Genet (2011) 0.86
Impairment of mitochondria in adult mouse brain overexpressing predominantly full-length, N-terminally acetylated human α-synuclein. PLoS One (2013) 0.86
Pesticides, microglial NOX2, and Parkinson's disease. J Biochem Mol Toxicol (2013) 0.86
Parkinson's disease mouse models in translational research. Mamm Genome (2011) 0.85
Differential regional expression patterns of α-synuclein, TNF-α, and IL-1β; and variable status of dopaminergic neurotoxicity in mouse brain after Paraquat treatment. J Neuroinflammation (2011) 0.85
Alpha-synuclein functions in the nucleus to protect against hydroxyurea-induced replication stress in yeast. Hum Mol Genet (2011) 0.84
How Parkinsonian toxins dysregulate the autophagy machinery. Int J Mol Sci (2013) 0.84
Astrocyte mediated protection of fetal cerebral cortical neurons from rotenone and paraquat. Environ Toxicol Pharmacol (2012) 0.83
Alpha-synuclein aggregation induced by brief ischemia negatively impacts neuronal survival in vivo: a study in [A30P]alpha-synuclein transgenic mouse. J Cereb Blood Flow Metab (2010) 0.83
Insights into the effects of alpha-synuclein expression and proteasome inhibition on glutathione metabolism through a dynamic in silico model of Parkinson's disease: validation by cell culture data. Free Radic Biol Med (2008) 0.82
Considerations on the role of environmental toxins in idiopathic Parkinson's disease pathophysiology. Transl Neurodegener (2014) 0.80
Gene-environment interaction models to unmask susceptibility mechanisms in Parkinson's disease. J Vis Exp (2014) 0.80
Is Alpha-Synuclein Loss-of-Function a Contributor to Parkinsonian Pathology? Evidence from Non-human Primates. Front Neurosci (2016) 0.80
Molecular chaperones, α-synuclein, and neurodegeneration. Mol Neurobiol (2012) 0.79
Macroautophagy and the proteasome are differently involved in the degradation of alpha-synuclein wild type and mutated A30P in an in vitro inducible model (PC12/TetOn). Neuroscience (2011) 0.78
AMP-activated protein kinase deficiency rescues paraquat-induced cardiac contractile dysfunction through an autophagy-dependent mechanism. Toxicol Sci (2014) 0.78
Brevetoxin-induced neural insult in the retrosplenial cortex of mouse brain. Inhal Toxicol (2006) 0.78
Nanomolar concentration of alpha-synuclein enhances dopaminergic neuronal survival via Akt pathway. Neural Regen Res (2013) 0.78
Mini review: linkage between α-Synuclein protein and cognition. Transl Neurodegener (2015) 0.77
Differential contribution of lipoxygenase isozymes to nigrostriatal vulnerability. Neuroscience (2012) 0.77
Identification and localization of alpha-synuclein in human cornea. Korean J Ophthalmol (2008) 0.77
Chronic Treatment with Paraquat Induces Brain Injury, Changes in Antioxidant Defenses System, and Modulates Behavioral Functions in Zebrafish. Mol Neurobiol (2016) 0.76
Parkinsonian toxin-induced oxidative stress inhibits basal autophagy in astrocytes via NQO2/quinone oxidoreductase 2: Implications for neuroprotection. Autophagy (2015) 0.76
Dopamine and paraquat enhance α-synuclein-induced alterations in membrane conductance. Neurotox Res (2011) 0.76
Comparison of independent screens on differentially vulnerable motor neurons reveals alpha-synuclein as a common modifier in motor neuron diseases. PLoS Genet (2017) 0.75
Changes in the sympathetic innervation of the gut in rotenone treated mice as possible early biomarker for Parkinson's disease. Clin Auton Res (2016) 0.75
Reverse genetics for proteomics: from proteomic discovery to scientific content. J Neural Transm (Vienna) (2006) 0.75
Animal models of α-synucleinopathy for Parkinson disease drug development. Nat Rev Neurosci (2017) 0.75
Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis (2002) 2.83
Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci (2007) 2.28
The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem (2001) 1.99
Lysosomal degradation of alpha-synuclein in vivo. J Biol Chem (2010) 1.82
Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype. Eur J Neurosci (2003) 1.77
Role of oxidative stress in paraquat-induced dopaminergic cell degeneration. J Neurochem (2005) 1.59
Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp Neurol (2002) 1.51
Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiol Dis (2006) 1.43
Mechanistic approaches to Parkinson's disease pathogenesis. Brain Pathol (2002) 1.39
MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology. PLoS One (2008) 1.39
Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry (2003) 1.33
Redox cycling of the herbicide paraquat in microglial cultures. Brain Res Mol Brain Res (2005) 1.27
Dieldrin exposure induces oxidative damage in the mouse nigrostriatal dopamine system. Exp Neurol (2007) 1.24
The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropathol Exp Neurol (2007) 1.21
Aging of the nigrostriatal system in the squirrel monkey. J Comp Neurol (2004) 1.20
Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. J Immunol (2008) 1.18
Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. Neurobiol Aging (2006) 1.18
Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease. FASEB J (2004) 1.13
Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo. J Biol Chem (2010) 1.11
Increased vulnerability of nigrostriatal terminals in DJ-1-deficient mice is mediated by the dopamine transporter. Neurobiol Dis (2007) 1.11
Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLoS One (2010) 1.08
Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. J Neurochem (2006) 1.06
Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation. J Biol Chem (2006) 1.06
Gene-environment interactions in Parkinson's disease and other forms of parkinsonism. Neurotoxicology (2010) 1.06
Caudo-rostral brain spreading of α-synuclein through vagal connections. EMBO Mol Med (2013) 1.02
Pathologic modifications of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys. J Neuropathol Exp Neurol (2008) 1.01
Effects of L-dopa and other amino acids against paraquat-induced nigrostriatal degeneration. J Neurochem (2003) 1.00
Paraquat neurotoxicity is mediated by a Bak-dependent mechanism. J Biol Chem (2007) 1.00
Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. Neurobiol Dis (2005) 1.00
The Webcam system: a simple, automated, computer-based video system for quantitative measurement of movement in nonhuman primates. J Neurosci Methods (2005) 0.96
Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann Neurol (2006) 0.95
Nicotine partially protects against paraquat-induced nigrostriatal damage in mice; link to alpha6beta2* nAChRs. J Neurochem (2007) 0.94
Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies. J Neurochem (2013) 0.93
Toxicity of redox cycling pesticides in primary mesencephalic cultures. Antioxid Redox Signal (2005) 0.90
Methionine oxidation stabilizes non-toxic oligomers of alpha-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions. Biochim Biophys Acta (2009) 0.90
Compromised reactive microgliosis in MPTP-lesioned IL-6 KO mice. Brain Res (2003) 0.88
Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys. J Pharmacol Exp Ther (2004) 0.87
Decreased alpha-synuclein expression in the aging mouse substantia nigra. Exp Neurol (2009) 0.87
Restorative effects of platelet derived growth factor-BB in rodent models of Parkinson's disease. J Parkinsons Dis (2011) 0.86
Comparison of the neurotoxic effects of proteasomal inhibitors in primary mesencephalic cultures. Exp Neurol (2006) 0.86
The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. J Neuropathol Exp Neurol (2007) 0.86
Neuron-to-neuron α-synuclein propagation in vivo is independent of neuronal injury. Acta Neuropathol Commun (2015) 0.84
α-Synuclein elevation in human neurodegenerative diseases: experimental, pathogenetic, and therapeutic implications. Mol Neurobiol (2012) 0.84
Enhanced alpha-synuclein expression in human neurodegenerative diseases: pathogenetic and therapeutic implications. Curr Protein Pept Sci (2009) 0.84
Nigrostriatal dopaminergic neurodegeneration in the weaver mouse is mediated via neuroinflammation and alleviated by minocycline administration. J Neurosci (2006) 0.83
The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates. Exp Neurol (2007) 0.81
Paraquat exposure reduces nicotinic receptor-evoked dopamine release in monkey striatum. J Pharmacol Exp Ther (2008) 0.80
Letter regarding: "Paraquat: the red herring of Parkinson's disease research". Toxicol Sci (2007) 0.80
L-DOPA does not cause neurotoxicity in VMAT2 heterozygote knockout mice. Neurotoxicology (2002) 0.79
Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration. Exp Neurol (2003) 0.77
Evidence of oxidative stress in young and aged DJ-1-deficient mice. FEBS Lett (2013) 0.76
Dyskinesias in normal squirrel monkeys induced by nomifensine and levodopa. Neuropharmacology (2005) 0.75